Efficacy and safety of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated *Plasmodium falciparum* malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials

Dawit Getachew Assefa1,2*, Eden Dagnachew Zeleke1,3, Delayeu Bekele1,4, Hanna Amanuel Tesfahune1,5, Emnet Getachew1,6, Michele Joseph1 and Tsegahun Manyazewal1

**Abstract**

**Background:** The emergence of artemisinin resistance in Southeast Asia and *Plasmodium falciparum kelch13* propeller gene mutations in sub-Saharan African pose the greatest threat to global efforts to control malaria. This is a critical concern in Uganda, where artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated falciparum. The objective of this study was to compare the efficacy and safety of dihydroartemisinin–piperaquine (DHA–PQ) and artemether–lumefantrine (AL) for the treatment of uncomplicated falciparum malaria in Ugandan children.

**Methods:** A search of PubMed and the Cochrane Central Register of Controlled Trials for retrieving randomized controlled trials comparing the efficacy and safety of DHA–PQ and AL for treatment of uncomplicated falciparum malaria in Ugandan children was done. The search was performed up to 31 August 2020. The data extracted from eligible studies and pooled as risk ratio (RR) with a 95% confidence interval (CI), using Rev Man Software (5.4). The protocol was registered in PROSPERO, ID: CRD42020182354.

**Results:** Eleven trials were included in this review and two of them only included under safety outcome. Total 3798 participants were enrolled. The PCR unadjusted treatment failure was significantly lower with DHA–PQ at day 28 (RR 0.30, 95% CI 0.19–0.49; participants = 7863; studies = 5; I² = 93%, low quality evidence) and at day 42 (RR 0.53, 95% CI 0.38–0.76; participants = 1618; studies = 4; I² = 79%, moderate quality of evidence). The PCR adjusted treatment failure at day 42 was significantly lower with DHA–PQ treatment group (RR 0.45, 95% CI 0.28 to 0.72; participants = 1370; studies = 5, high quality of evidence), and it was below 5% in both arms at day 28 (moderate quality of evidence). AL showed a longer prophylactic effect on new infections which may last for up to 63 days (PCR-adjusted treatment
Since 2004, all malaria-endemic countries have gradually updated their treatment policy from mono-therapy to the currently recommended artemisinin-based combinations [1]. The drug combinations include short-acting artemisinin derivatives, such as artesunate, artemether, or dihydroartemisinin, in combination with long-acting drugs. The artemisinin component covers two asexual cycles and rapidly decrease parasitaemia by a factor of approximately 10,000 in each 48-h asexual cycle. It is also active against the sexual stages that facilitate forward transmission to mosquitoes. Over several weeks after treatment, the partner drug eliminates residual parasites [6].

While the anti-malarial efficacies of presently endorsed artemisinin-based combinations have been excellent in Africa [8, 9], resistance to ACT in Southeast Asia has become an emerging concern [10]. In 2009, a reduction in parasite clearance rate by 100-fold was reported in western Cambodia, exhibiting artemisinin resistance [10]. Since then, artemisinin resistance has been defined as a parasite clearance half-life of ≥5 h cut-off after treatment with ACT or artesunate monotherapy [11]. Slow parasite clearance signifies a “partial” resistance that is articulated only in early-ring-stage parasites [12, 13]. Late parasite clearance following treatment with artesininins, mediated predominantly by mutations in the kelch13 (k13) gene, was detected in the Greater Mekong Sub-region and dozens of k13-propeller mutations have been detected at very low frequency in 18 countries in sub-Saharan Africa [14].

Dihydroartemisinin–piperaquine (DHA–PQ) is a promising artemisinin-based combination recently endorsed by the World Health Organization (WHO) as a potential alternative treatment for uncomplicated malaria in Africa. Several clinical trials have revealed that DHA–PQ is safe and efficacious for treatment of uncomplicated malaria [15–18], but analysis of cardiac adverse events in clinical trials showed that QTc prolongation were reported more frequently in DHA–PQ treated patients than in those treated with comparator anti-malarial [19]. The pharmacokinetics and pharmacodynamics of the combination therapy for adults are well documented; however, there have been inconsistencies of these potential effects in children. The emergence of artemisinin resistance in Southeast Asia and P. falciparum k13 mutations in sub-Saharan African pose the greatest threat to global efforts to control malaria [10, 11, 13, 20]. This is a critical concern in Uganda, where ACT medicines is the first-line treatment option for uncomplicated falciparum. Additionally, in Uganda and other sub-Saharan African countries, malaria-HIV co-infection is associated with an increased frequency of clinical parasitaemia, increased parasite and viral load, impaired immunity to malaria in children, and impaired anti-malarial drug efficacy [21, 22]. The potential benefits of DHA–PQ over other artemisinin-based combinations...
make it necessary to investigate this further among children in Uganda. This systematic review and meta-analysis of randomized control trials aimed to synthesize the evidence on the efficacy and safety of DHA–PQ versus AL for the treatment of uncomplicated *P. falciparum* malaria in Ugandan children.

**Methods**
The protocol for this systematic review and meta-analysis has been registered at the International Prospective Register of Systematic Reviews (PROSPERO) database, ID: CRD42020182354 [24]. The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA 2015) guidelines [25] was followed to choose studies to be included in this review.

**Eligibility criteria**
The studies included were randomized controlled trials conducted in Uganda that evaluated the efficacy and safety of DHA–PQ versus AL for treatment of uncomplicated falciparum malaria in children, written in English and published between 01 January 2004 to 31 August 2020. Eligible studies were identified through the PICOS format [26].

**Participants**
Children having uncomplicated falciparum malaria residing in Uganda, regardless of gender, were included.

**Interventions**
A target dose (range) of 4 (2–10) mg/kg bw per day dihydroartemisinin and 18 (16–27) mg/kg bw per day piperaquine given once a day for 3 days for adults and children weighing ≥ 25 kg. The target doses and ranges for children weighing < 25 kg are 4 (2.5–10) mg/kg bw per day dihydroartemisinin and 24 (20–32) mg/kg bw per day piperaquine once a day for 3 days.

**Comparator**
A total dose of 5–24 mg/kg bw of artemether and 29–144 mg/kg bw of lumefantrine. Artemether + lumefantrine is given twice a day for 3 days (total, six doses). The first two doses should, ideally, be given 8 h apart.

**Outcome measures**

**Primary outcomes**
The treatment outcome was determined according to the classification of WHO Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations [27] classified as:

- Early treatment failure (ETF): The development of danger signs or severe malaria on days 1, 2, or 3 in the presence of parasitaemia; or parasitaemia on day 2 higher than on day 0; or parasitaemia and axillary temperature > 37.5 °C on day three; or parasitaemia on day 3 > 20% of count on day 0 or development of danger signs, or severe malaria, after day 3 with parasitaemia; or presence of *P. falciparum* parasitaemia and axillary temperature > 37.5 °C on or after day 4; or presence of *P. falciparum* parasitaemia after day 7.

- Late clinical failure (LCF): Danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 28 (day 42) in patients who did not previously meet any of the criteria for early treatment failure; or Presence of parasitaemia on any day between day 4 and day 28 (day 42) with axillary temperature ≥ 37.5 °C in patients who did not previously meet any of the criteria for early treatment failure.

- Late parasitological failure (LPF): Presence of parasitaemia on any day between day 7 and day 28 (day 42) with axillary temperature < 37.5 °C in patients who did not previously meet any of the criteria for early treatment failure or late clinical failure.

- Adequate clinical and parasitological response (ACPR): Before and after Polymerase Chain Reaction (PCR) correction used to show the treatment success and it defined as absence of parasitaemia by the end of treatment (day 28) regardless of axillary temperature without previously meeting any of the benchmarks of early treatment failure or late clinical failure or late parasite logical failure.

- PCR genotyping was used to define treatment failure corresponding to current WHO recommendations [27]. Adverse events including serious adverse events were also assessed.

**PCR-unadjusted total failure (P. falciparum):** Was calculated as the sum of late treatment failures and early treatment failures (without PCR adjustment). The denominator was excluding participants who did not satisfy the inclusion criteria after randomization and those outcomes not available (for example, those who were lost to follow-up, withdrew consent, other species infection, took another anti-malarial, or failed to complete treatment).

**PCR-adjusted total failure (P. falciparum):** Was calculated as the sum of early treatment failures plus late treatment failures due to PCR-confirmed recrudescence. Participants with indeterminate PCR results, missing PCR results or PCR-confirmed new infections were measured to be involuntary withdrawals and excluded them from the calculation. The denominator excludes participants who did not satisfy the inclusion criteria after randomization, participants with (falciparum reinfection, other species mixed with falciparum reinfection, and undetermined or missing PCR) and those participants for whom an outcome was not available (for example, those who were lost to follow-up, withdrew consent,
Other species infection, took another anti-malarial, or failed to complete treatment).

Secondary outcomes
Fever clearance: The proportion of patients febrile on each day within 3 days.
Parasite clearance: The proportion of patients clear of parasites on each day within 3 days,
Gametocyte carriage at Baseline and Day 14 or 28 or 42, and
Change in serum hemoglobin level from baseline (minimum 28 days and 42 days follow-up) were also evaluated.

Search strategy
A computerized systematic search method was used to search for articles from PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL). The search was limited to human studies and published in English language until 31 August 2020. Additionally, we searched ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, and the US Food and Drug Administration (FDA) to search and assess ongoing or unpublished trials.
The search strategies in PubMed for the MeSH terms and text words was ‘uncomplicated malaria in children’ [MeSH Terms] OR ‘uncomplicated Plasmodium falciparum malaria in children’ [MeSH Terms] OR ‘falciparum malaria in children’ [MeSH Terms] OR ‘asymptomatic malaria in children’ [MeSH Terms] AND ‘artemisinin based combination therapy’ [MeSH Terms] OR ‘artemisinin’ [MeSH Terms] OR ‘artemether lumefantrine’ [MeSH Terms] OR ‘coartem’ [MeSH Terms] OR ‘dihydroartemisinin piperaquine’ [MeSH Terms] OR ‘Duocotexin’ [MeSH Terms] OR ‘Eurartesim’ [MeSH Terms] OR ‘D-Artepp’ [MeSH Terms])) AND ‘randomized controlled trial’ [MeSH Terms] OR ‘controlled clinical trial’ [MeSH Terms] OR ‘randomized’ [MeSH Terms] OR ‘drug therapy’[MeSH Terms] OR ‘trial’ [MeSH Terms] OR ‘groups’ [MeSH Terms] OR ‘humans’ [MeSH Terms]).

Study selection, data collection, and data analysis
The Cochrane Handbook for Systematic Reviews of Interventions [28], the RevMan 5.4 software, and the EndNote X7 were used for data management and analysis. Two authors independently reviewed the results and disagreements resolved through discussion. When clarification was necessary, the trial authors were contacted.

Data extraction and management
The title and abstract were produced from the electronic search and independently screened by two authors based on RCTs that were assessed human falciparum malaria. The information collected were trial characteristics including methods, participants, interventions, and outcomes as well as data on dose and drug ratios of the combinations. Relevant information such as title, name of the journal, year of publication, publication status, study design, study setting, follow-up period, sample size, funding source, baseline characteristics of study subjects, fever clearance, parasite clearance, treatment failure, and gametocyte carriage were extracted from each article using a structured data extraction format adapted from Cochrane. The number of participants randomized and the number analysed in each treatment group for each outcome were also captured. Two authors independently extracted the data and cross-checked. For dichotomous outcomes, the number of participants experiencing the event and the number of participants in each treatment group were documented. For continuous outcomes, the arithmetic means and standard deviations for each treatment group collectively with the numbers of participants in each group were extracted.

Assessment of risk of bias in included studies
The risk of bias for each trial was evaluated by two authors independently using the Cochrane Collaboration’s tool for assessing the ‘Risk of bias’ [26]. The risks were classified as high risk, unclear risk, and low risk.

Measures of treatment effect
The main outcomes in this review were total treatment failure at days 28, 42, and 63; PCR-adjusted and PCR unadjusted. Dichotomous data were combined and presented using risk ratios. Continuous data were summarized by arithmetic means and standard deviations, and then data were combined using mean differences. Risk ratios and mean differences were accompanied by 95% CIs. In the forest plot, the upper and the bottom tips of the diamond (the centre of the diamond) represents point estimate and the left and right tips of the diamond represents confidence interval. Also, the treatment arm is on the left side and the one in the right side is comparator arm.

Assessment of heterogeneity
Heterogeneity among trials was assessed by inspecting the forest plots (to detect overlapping CI) and the Cochrane Q and I² statistic were used to measure heterogeneity among the trials in each analysis, the Chi² test with a P < 0.10 to indicate statistical significance was used, and the results were interpreted following Cochrane Handbook for Systematic Reviews
of Interventions Version 6.0, Chapter 10: Analyzing data and undertaking meta-analyses [29]. When substantial heterogeneity ($I^2 > 50\%$) was identified, it was reported, and explored the possible causes by subgroup analyses.

**Data synthesis**
The meta-analyses were done consistent with the recommendations of Cochrane [28]. To aid interpretation, included trials were given identity codes including the first author and the year of publication. Trials were enumerated in forest plots in chronological order of the year the trials were published. A random-effects model was used, as trials were done by different researchers, operating independently, and it could be implausible that all the trials had functionally equivalent, with a common effect estimate.

**Subgroup analysis and investigation of heterogeneity**
The potential sources of heterogeneity were investigated through the following subgroup analyses: the known studies with HIV negative participants were compared to studies with both HIV negative and positive participants in the overall assessment because HIV infection has an effect of parasite clearance [30].

**Sensitivity analysis**
Studies only with low risk of bias were included and to assess the small study effect, the fixed-effect and random-effect estimates of the intervention were compared.

**Quality of evidence**
Quality of evidence was assessed using GRADE criteria and the GRADE pro software [31]. The results were presented in a ‘Summary of Findings’ table. Randomized trials are initially categorized as high quality but downgraded after assessment of five criteria [32]. The levels of evidence were defined as ‘high,’ ‘moderate,’ ‘low,’ or ‘very low.’ The recommendations of Section 8.5 and Chapter 13 of the Cochrane Handbook for Systematic Reviews of Interventions was followed [33]. The imprecision was judged based on the optimal information size criteria and CI [34].
Results
Search results
A total of 488 trials through the databases were searched, of which 52 full-text trials for eligibility were assessed and found 10 of them fulfilled the inclusion criteria for meta-analysis and an additional one for qualitative analysis (Fig. 1).

Study characteristics
In this review, 11 trials were included, which enrolled 3981 participants with uncomplicated *P. falciparum* malaria were included in this review (Table 1).

Methodological quality and risk of bias
The 'Risk of bias' assessments were summarized in Fig. 2.

Effect of interventions
Fever clearance

**Fever clearance at Day 1**
Six studies with 2978 were reported in this outcome, but the pooled result showed considerable heterogeneity between studies. The result of studies was heterogeneous (RR 0.87, 95% CI 0.75 to 1.01; participants = 2978; studies = 6; I^2 = 78%). Four trials with HIV negative participants, in two studies [40, 41] the patients treated with DHA–PQ experienced high resolution of fever than AL (RR 0.81 95% CI 0.70 to 0.95 and RR 0.90 95% CI 0.82 to 1.00) and one study [39] no significant difference was found between the two intervention groups (RR 1.00 95% CI 0.87 to 1.14). However, another study [37] reported that the patients treated with AL experienced high

**PCR-unadjusted total failure at day 42** At day 42, PCR unadjusted treatment failure in four trails [35, 39–41] (participants = 1618) were significantly lower in the DHA–PQ group than the AL group (RR 0.53, 95% CI 0.38 to 0.76; participants = 1618; studies = 4; I^2 = 79%). The result had considerable heterogeneity and we couldn't pool the result. The PCR unadjusted treatment failures for the individual studies were: 0.79 (95% confidence interval 0.65, 0.97 [39]); 0.39 (95% confidence interval 0.24 to 0.63 [40]); 0.36 (95% confidence interval 0.21, 0.63, [35]) and 0.56 (95% confidence interval 0.44 to 0.70, [41], Fig. 5).

**PCR-adjusted total failure at day 42** The overall PCR adjusted treatment failures was lower for participants treated with DHA–PQ than those treated with AL (RR 0.45, 95% CI 0.28 to 0.72; participants = 1370; studies = 5; I^2 = 3%, Fig. 6).

**PCR-unadjusted total failure at day 63** The PCR unadjusted treatment failure was not statistically different between the two treatment groups (RR 0.59, 95% CI 0.25 to 1.37; participants = 1514; studies = 2; I^2 = 96%). The result had considerable heterogeneity. It is more useful to consider individual trial results. At day 63, in one study [36] the PCR unadjusted treatment failure in DHA–PQ arm was significantly lower than those treated with AL RR 0.38 (95% confidence interval 0.28 to 0.52) and although, no significant difference was found between the two treatment group in the other trial [35] 0.88 (95% confidence interval 0.77 to 1.02, Additional file 1: S1).

**PCR-adjusted total failure at day 63** The pooled PCR adjusted treatment failure in participants treated with AL was significantly lower than those who are treated with DHA–PQ (RR 2.04, 95% CI 1.13 to 3.70; participants = 1311; studies = 2; I^2 = 0%, Additional file 2: S2).

Effect of interventions

**Treatment failure**

**PCR-unadjusted total failure at day 28** At day 28, PCR PCR unadjusted treatment failures in five studies [30, 35–38] was significantly lower for participants treated with DHA–PQ than for those treated with AL (RR 0.30, 95% CI 0.19 to 0.49; participants = 7863; studies = 5; I^2 = 93%, Fig. 3). There was considerable heterogeneity between the studies. To investigate the cause of heterogeneity, the subgroup analyses have done based on the HIV status of the participants in the included studies.

At day 28, in two studies with HIV negative participants, the PCR unadjusted treatment failures was significantly lower for participants treated with DHA–PQ than those treated with AL (RR 0.52, 95% CI 0.39 to 0.70; participants = 949; studies = 2; I^2 = 25%, Fig. 3).

Consistently, in three studies (participants = 6914; [30, 35, 38]) with both HIV negative and positive participants, the PCR unadjusted treatment failures was significantly lower for participants treated with DHA–PQ than those treated with AL. The results were highly heterogeneous (Heterogeneity: Tau^2 = 0.06; Chi^2 = 9.11, df = 2 (P = 0.01); I^2 = 78%). Relative risks for the individual studies were: 0.33 (95% confidence interval 0.23 to 0.46, [35]); 0.17 (95% confidence interval 0.12 to 0.24, [30]); and 0.20 (95% confidence interval 0.18 to 0.22, [38]). Hence, statistically significant difference was found between the two subgroups (Chi^2 = 14.52, df = 1 (P = 0.0001), I^2 = 93.1%, Fig. 3).

**PCR-adjusted total failure at day 28** At day 28, the PCR adjusted treatment failures was below 5% in both treatment arms without significant difference between the two treatment groups (RR 0.70, 95% CI 0.40 to 1.23; participants = 2411; studies = 5; I^2 = 0%, Fig. 4).
| S. no. | Author, Publication year | Study design | Study setting and period | Follow up | Subjects | Patient important outcome | DHA–PQ | AL |
|-------|--------------------------|--------------|--------------------------|-----------|----------|--------------------------|--------|----|
|       |                          |              |                          |           | Number of participants | Inclusion age |
|       |                          |              |                          |           | DHA–PQ | AL |
| 1     | Kamya, 2007 [39]         | Single blind RCT | Rural health center, March, 2006–July, 2006 | 42 days | 253 | 256 | 6 months–10 years | Loss to follow up | 0 | 0 |
|       |                          |              |                          |           | ETF | 0 | 0 |
|       |                          |              |                          |           | LCF | 19 | 30 |
|       |                          |              |                          |           | LPF | 73 | 89 |
|       |                          |              |                          |           | ACP | 117 | 89 |
|       |                          |              |                          |           | Fever clearance at day 1 | 137 | 137 |
|       |                          |              |                          |           | Fever clearance at day 2 | 66 | 72 |
|       |                          |              |                          |           | Fever clearance at day 3 | 52 | 57 |
|       |                          |              |                          |           | Parasite clearance at day 2 | 1 | 2 |
|       |                          |              |                          |           | Parasite clearance at day 3 | 0 | 0 |
|       |                          |              |                          |           | Gametocyte carriage at baseline | 9 | 18 |
|       |                          |              |                          |           | Gametocyte carriage day 1–14 | 5 | 2 |
|       |                          |              |                          |           | Gametocyte carriage day 15–28 | 0 | 5 |
|       |                          |              |                          |           | Gametocyte carriage day 29–41 | 4 | 11 |
|       |                          |              |                          |           | Hgb at baseline mean (SD) | 9.5 (1.8) | 9.7 (1.9) |
|       |                          |              |                          |           | Hgb g/dL at day 42 mean (SD)a | 1.9 (1.8) | 1.5 (1.8) |
|       |                          |              |                          |           | Vomiting | 65 | 65 |
|       |                          |              |                          |           | Diarrhea | 25 | 19 |
|       |                          |              |                          |           | Anorexia | 90 | 91 |
|       |                          |              |                          |           | Abdominal pain | 19 | 20 |
|       |                          |              |                          |           | Weakness/malaise | 85 | 103 |
|       |                          |              |                          |           | Cough | 136 | 133 |
|       |                          |              |                          |           | Coryza | 127 | 121 |
|       |                          |              |                          |           | Pruritus | 14 | 22 |
|       |                          |              |                          |           | SAE | 4 | 2 |
| S. no | Author, Publication year | Study design | Study setting and period | Follow up | Subjects | Patient important outcome | DHA–PQ | AL |
|-------|--------------------------|--------------|--------------------------|-----------|----------|--------------------------|--------|----|
| 2     | Yeka, 2008 [40]          | Single-blind RCT Health center, August 2006–April 2007 | 42 days | 234 | 227 | 6 months–10 years Los to follow up | 3 | 3 |
|       |                          |              |                          |           |          | ETF | 0 | 1 |
|       |                          |              |                          |           |          | LCF | 9 | 23 |
|       |                          |              |                          |           |          | LPF | 17 | 41 |
|       |                          |              |                          |           |          | ACPR | 186 | 131 |
|       |                          |              |                          |           |          | Fever clearance at day 1 | 117 | 133 |
|       |                          |              |                          |           |          | Fever clearance at day 2 | 44 | 37 |
|       |                          |              |                          |           |          | Fever clearance at day 3 | 22 | 22 |
|       |                          |              |                          |           |          | Parasite clearance at day 2 | 7 | 5 |
|       |                          |              |                          |           |          | Parasite clearance at day 3 | 0 | 0 |
|       |                          |              |                          |           |          | Gametocyte carriage at baseline | 12 | 18 |
|       |                          |              |                          |           |          | Gametocyte carriage day 1–14 | 4 | 1 |
|       |                          |              |                          |           |          | Gametocyte carriage day 15–28 | 1 | 7 |
|       |                          |              |                          |           |          | Gametocyte carriage day 29–41 | 4 | 13 |
|       |                          |              |                          |           |          | Hgb at baseline mean (SD) | 99 (2.1) | 99 (1.8) |
|       |                          |              |                          |           |          | Hgb at day 42 mean (SD)<sup>a</sup> | 18 (1.8) | 1.7 (2.0) |
|       |                          |              |                          |           |          | Vomiting | 35 | 35 |
|       |                          |              |                          |           |          | Diarrhea | 26 | 23 |
|       |                          |              |                          |           |          | Anorexia | 47 | 49 |
|       |                          |              |                          |           |          | Abdominal pain | 17 | 24 |
|       |                          |              |                          |           |          | Weakness/malaise | 28 | 27 |
|       |                          |              |                          |           |          | Cough | 164 | 150 |
|       |                          |              |                          |           |          | Coryza | 159 | 150 |
|       |                          |              |                          |           |          | Pruritus | 8 | 3 |
|       |                          |              |                          |           |          | SAE | 5 | 2 |
| S. no. | Author, Publication year | Study design | Study setting and period | Follow up | Subjects | Patient important outcome | DHA–PQ | AL |
|-------|--------------------------|--------------|--------------------------|-----------|----------|--------------------------|--------|
| 3     | Arinaitwe, 2009 [35]     | Open-label RCT | Local antenatal clinics in Tororo, August 2007–July 2008 | 63 days   | 119      | 111 | 6 weeks–12 months | Other anti-malaria use | 1 | 2 |
|       |                          |              |                          |           |          |                            |        |
|       |                          |              |                          |           |          | Loss to follow up | 5 | 2 |
|       |                          |              |                          |           |          | Complicated malaria at day 0 | 0 | 1 |
|       |                          |              |                          |           |          | Recurrent malaria caused by non-falciparum species | 0 | 1 |
|       |                          |              |                          |           |          | ETF | 0 | 0 |
|       |                          |              |                          |           |          | LCF | 13 | 45 |
|       |                          |              |                          |           |          | LPF | 26 | 64 |
|       |                          |              |                          |           |          | ACPR | 306 | 205 |
|       |                          |              |                          |           |          | Fever clearance at day 1 | 138 | 163 |
|       |                          |              |                          |           |          | Fever clearance at day 2 | 13 | 17 |
|       |                          |              |                          |           |          | Fever clearance at day 3 | 9 | 12 |
|       |                          |              |                          |           |          | Parasite clearance at day 2 | 12 | 22 |
|       |                          |              |                          |           |          | Parasite clearance at day 3 | 1 | 0 |
|       |                          |              |                          |           |          | Gametocyte carriage at baseline | 30 | 26 |
|       |                          |              |                          |           |          | Gametocyte carriage day 1–14 | 10 | 1 |
|       |                          |              |                          |           |          | Gametocyte carriage at day 15–28 | 1 | 0 |
|       |                          |              |                          |           |          | Hgb at baseline mean (SD) | 9.9 (1.5) | 9.8 (1.5) |
|       |                          |              |                          |           |          | Hgb at day 28 mean (SD) | 0.6 (1.68) | 0.6 (1.56) |
|       |                          |              |                          |           |          | Vomiting | 23 | 20 |
|       |                          |              |                          |           |          | Diarrhea | 79 | 86 |
|       |                          |              |                          |           |          | Anorexia | 3 | 0 |
|       |                          |              |                          |           |          | Weakness | 1 | 0 |
|       |                          |              |                          |           |          | Cough | 177 | 153 |
|       |                          |              |                          |           |          | Pruritus | 0 | 0 |
|       |                          |              |                          |           |          | SAE | 3 | 1 |

| 4     | Bassat, 2009 [76]       | Open-label RCT (non-inferiority) | Rural sites and one peri-urban site, August 2005–July 2006 | 42 days   | 164      | 82 | 6–59 months | PCR-corrected ACPR day 28 | 155 | 77 |
|       |                          |              |                          |           |          | PCR-corrected ACPCR day 42 | 154 | 77 |
| S. no. | Author, Publication year | Study design | Study setting and period | Follow up | Number of participants | Inclusion age | Subjects | Patient important outcome | DHA–PQ AL |
|--------|--------------------------|--------------|--------------------------|-----------|------------------------|--------------|---------|--------------------------|-----------|
| 5      | Katrak, 2009 [42]        | Open-label RCT | N/A, August, 2007–April, 2008 | N/A       | 124                    | 6 weeks–12 months | 122     | Vomiting                 | 19        |
|        |                          |              |                          |           |                        |              |         | Diarrhea                 | 64        |
|        |                          |              |                          |           |                        |              |         | Cough                    | 200       |
|        |                          |              |                          |           |                        |              |         | SAE                      | 3         |
| 6      | 4ABC, 2011 [36]          | Open-label RCT | N/A, July 2007–June 2009  | 63 days   | 422                    | 6–59 months  | 421     | Day 28 PCR-unadjusted ACPR | 360       |
|        |                          |              |                          |           |                        |              |         | Day 28 PCR-adjusted ACPR | 407       |
|        |                          |              |                          |           |                        |              |         | Day 63 PCR-unadjusted ACPR | 234       |
|        |                          |              |                          |           |                        |              |         | Day 63 PCR-adjusted ACPR | 375       |
| 7      | Yeka, 2013 [37]          | Single-blind RCT | Health center, December, 2007–April, 2009 | 28 days | 72                     | 6–59 months  | 35      | Fever clearance at day 1 | 48        |
|        |                          |              |                          |           |                        |              |         | Fever clearance at day 2 | 15        |
|        |                          |              |                          |           |                        |              |         | Fever clearance at day 3 | 4         |
|        |                          |              |                          |           |                        |              |         | Parasite clearance at day 2 | 2         |
|        |                          |              |                          |           |                        |              |         | Parasite clearance at day 3 | 0         |
|        |                          |              |                          |           |                        |              |         | Gametocyte carriage at baseline | 0         |
|        |                          |              |                          |           |                        |              |         | Gametocyte carriage day 1–14 | 0         |
|        |                          |              |                          |           |                        |              |         | Gametocyte carriage at day 15–28 | 0         |
|        |                          |              |                          |           |                        |              |         | Hgb at baseline mean (SD) | 108 (134) |
|        |                          |              |                          |           |                        |              |         | Hgb at day 28 mean (SD) | 106 (1.7) |
|        |                          |              |                          |           |                        |              |         | Vomiting                  | 3         |
|        |                          |              |                          |           |                        |              |         | Diarrhea                  | 1         |
|        |                          |              |                          |           |                        |              |         | Anorexia                  | 12        |
|        |                          |              |                          |           |                        |              |         | Abdominal pain            | 5         |
|        |                          |              |                          |           |                        |              |         | Weakness/malaise           | 1         |
|        |                          |              |                          |           |                        |              |         | Cough                      | 47        |
|        |                          |              |                          |           |                        |              |         | SAE                        | 0         |
| S. no. | Author, Publication year | Study design | Study setting and period | Follow up | Subjects | Patient important outcome | DHA–PQ | AL |
|--------|--------------------------|--------------|--------------------------|-----------|----------|--------------------------|---------|----|
|        |                          |              |                          |           | Number of participants | Inclusion age |
|        |                          |              |                          |           | DHA–PQ   | AL |
| 8      | Kakuru, 2014 [77] | RCT          | District Hospital, August 2007 and April 2008 | N/A       | 21       | 22 | 6 weeks–12 months | Loss to follow up |
|        |                          |              |                          |           | ETF      | 0  | 0 |
|        |                          |              |                          |           | LCF      | 3  | 19 |
|        |                          |              |                          |           | LPF      | 11 | 53 |
|        |                          |              |                          |           | ACPR     | 149| 127|
|        |                          |              |                          |           | Fever clearance at day 1 | 46 | 106 |
|        |                          |              |                          |           | Fever clearance at day 2 | 7  | 16 |
|        |                          |              |                          |           | Fever clearance at day 3 | 5  | 3 |
|        |                          |              |                          |           | Parasite clearance at day 2 | 5  | 32 |
|        |                          |              |                          |           | Parasite clearance at day 3 | 1  | 3 |
|        |                          |              |                          |           | Gametocyte carriage at baseline | 15 | 9 |
|        |                          |              |                          |           | Gametocyte carriage at day 15–28 | 30 | 15 |
|        |                          |              |                          |           | Hgb at baseline mean (SD) | 96 (1.5) | 101 (1.4) |
|        |                          |              |                          |           | Hgb at day 28 mean (SD) | 10 (1.4) | 0.6 (1.5) |
|        |                          |              |                          |           | Vomiting | 8  | 18 |
|        |                          |              |                          |           | Diarrhea | 27 | 23 |
|        |                          |              |                          |           | Anorexia | 6  | 4 |
|        |                          |              |                          |           | Weakness/malaise | 2  | 2 |
|        |                          |              |                          |           | Cough    | 64 | 74 |
**Table 1** (continued)

| S. no. | Author, Publication year | Study design | Study setting and period | Follow up | Subjects | Patient important outcome | DHA–PQ | AL |
|--------|--------------------------|--------------|--------------------------|-----------|----------|---------------------------|--------|
| 9      | Muhindo, 2014 [30]       | Open-label, RCT | October District Hospital, October 2011–December, 2012 | 28 days   | 106      | 6 weeks–12 months         | 16     |
|        |                          |              |                          |           | 96       |                           |        |
|        |                          |              |                          |           |          | Loss to follow up          | 13     |
|        |                          |              |                          |           |          | ETF                        | 1      |
|        |                          |              |                          |           |          | LCF                        | 7      |
|        |                          |              |                          |           |          | LPF                        | 22     |
|        |                          |              |                          |           |          | ACPR                       | 311    |
|        |                          |              |                          |           |          | Fever clearance at day 1   | 65     |
|        |                          |              |                          |           |          | Fever clearance at day 2   | 11     |
|        |                          |              |                          |           |          | Fever clearance at day 3   | 7      |
|        |                          |              |                          |           |          | Parasite clearance at day 1| 181    |
|        |                          |              |                          |           |          | Parasite clearance at day 2| 20     |
|        |                          |              |                          |           |          | Parasite clearance at day 3| 1      |
|        |                          |              |                          |           |          | Hgb at baseline mean (SD)   | 11.2 (1.5) |
|        |                          |              |                          |           |          | Other anti-malaria use     | 3      |
|        |                          |              |                          |           |          | Loss to follow up           | 21     |
|        |                          |              |                          |           |          | Withdrawn consent           | 1      |
|        |                          |              |                          |           |          | ETF                        | 2      |
|        |                          |              |                          |           |          | LCF                        | 48     |
|        |                          |              |                          |           |          | LPF                        | 182    |
|        |                          |              |                          |           |          | ACPR                       | 2403   |
| 10     | Wanzira, 2014 [38]       | Open-label, RCT | District Hospital, February 2009–2012 | 28 days   | 154      | 4 weeks–12 months         | 16     |
|        |                          |              |                          |           | 158      |                           |        |
|        |                          |              |                          |           |          | Loss to follow up           | 19     |
|        |                          |              |                          |           |          | Withdrawn consent           | 2      |
|        |                          |              |                          |           |          | ETF                        | 15     |
|        |                          |              |                          |           |          | LCF                        | 475    |
|        |                          |              |                          |           |          | LPF                        | 894    |
|        |                          |              |                          |           |          | ACPR                       | 1494   |
### Table 1 (continued)

| S. no. | Author, Publication year | Study design | Study setting and period | Follow up | Subjects | Patient important outcome | DHA–PQ | AL |
|--------|--------------------------|--------------|--------------------------|-----------|----------|--------------------------|---------|----|
| 11     | Yeka, 2019 [41]          | Single-blind RCT | Health center and Hospital, October 2015–December 2016 | 42 days   | 299 300 6–59 months | Fever clearance at day 1 | 208 231 |
|        |                          |              |                          | 299 300 6–59 months |           | Fever clearance at day 2 | 71 72   |
|        |                          |              |                          | 299 300 6–59 months |           | Fever clearance at day 3 | 31 18   |
|        |                          |              |                          | 299 300 6–59 months |           | Parasite clearance at day 1 | 219 245 |
|        |                          |              |                          | 299 300 6–59 months |           | Parasite clearance at day 2 | 22 34   |
|        |                          |              |                          | 299 300 6–59 months |           | Parasite clearance at day 3 | 3 3     |
|        |                          |              |                          | 299 300 6–59 months |           | Gametocyte carriage at baseline | 59 60 |
|        |                          |              |                          | 299 300 6–59 months |           | Gametocyte carriage at day 1–42 | 43 46 |
|        |                          |              |                          | 299 300 6–59 months |           | Hgb at day 42 mean (SD)a | 13 (1.69) 0.8 (1.8) |
|        |                          |              |                          | 299 300 6–59 months |           | Vomiting | 56 61 |
|        |                          |              |                          | 299 300 6–59 months |           | Diarrhea | 155 114 |
|        |                          |              |                          | 299 300 6–59 months |           | Anorexia | 12 3 |
|        |                          |              |                          | 299 300 6–59 months |           | Abdominal pain | 41 45 |
|        |                          |              |                          | 299 300 6–59 months |           | Headaches | 18 24 |
|        |                          |              |                          | 299 300 6–59 months |           | Weakness/malaise | 42 33 |
|        |                          |              |                          | 299 300 6–59 months |           | Cough | 233 203 |
|        |                          |              |                          | 299 300 6–59 months |           | Pallor | 22 13 |
|        |                          |              |                          | 299 300 6–59 months |           | Skin rash | 56 42 |
|        |                          |              |                          | 299 300 6–59 months |           | Pruritus | 24 16 |
|        |                          |              |                          | 299 300 6–59 months |           | SAE | 6 6 |

LTF: loss to follow up, ETF early treatment failure, LCT late clinical failure, LPF late parasitological failure, ACPR Adequate clinical and parasitological response, AL artemether–lumefantrine, DHA–PQ dihydroartemisinin–piperaquine, Hgb hemoglobin, SD standard deviation, PCR polymerase chain reaction, SAE serious adverse event, N/A not available.

a The mean increase in hemoglobin values from the baseline.
resolution of fever (RR 1.67 95% CI 1.08 to 2.58), Additional file 3: S3).

Two studies [30, 35] with both HIV negative and positive participants reported that more participants from DHA–PQ treatment group experienced fast resolution of fever (RR 0.71, 95% CI 0.57 to 0.88; participants = 1441; studies = 2; I² = 51%, Fig. 9). There was statistically significant difference found between the two subgroups (Chi² = 4.91, df = 1 (P = 0.03), I² = 79.6%).

Fever clearance at Day 2

By day 2 in five trials, the patients experienced high resolution of fever without a statistically significant difference between the two groups, and in one trial patients treated with DHA–PQ experienced high resolution of fever [37]. The results were highly heterogeneous (RR 0.84, 95% CI 0.61 to 1.16; participants = 2978; studies = 6; I² = 69%). Relative risks for the individual studies were: 0.35 (95% confidence interval 0.21, 0.59 [37]); 0.91 (95% confidence interval 0.69, 1.20 [39]); 1.10 (95% confidence interval 0.74, 1.63 [40]); 0.70 (95% confidence interval 0.34, 1.41 [35]); 1.62 (95% confidence interval 0.66, 3.97 [30]); and 0.99 (95% confidence interval 0.74, 1.32, [41], participants = 2978; studies = 6, Additional file 4: S4).

---

![Fig. 2](image_url)  
**Fig. 2** Risk of bias summary: ‘review authors’ judgments about each risk of bias item for each included study

![Fig. 3](image_url)  
**Fig. 3** Forest plot of comparison: Dihydroartemisinin piperazine versus artemether–lumefantrine, outcome: PCR-unadjusted treatment failures at day 28
Fever clearance at Day 3

The prevalence of fever was similar over 3 days of follow up in both treatment groups in two trials [37, 39]. The overall pooled result was (RR 1.01, 95% CI 0.80 to 1.27; participants = 2978; studies = 6; I² = 0%, Additional file 5: S5).

Parasite clearance

The percentage of patients with parasitaemia at day one in two trials was significantly lower in the DHA–PQ treatment group than AL (RR 0.85, 95% CI 0.75 to 0.97; participants = 1369; studies = 6; I² = 66%, Additional file 6: S6). However, at day 2 and 3, the overall result shows that the percentage of patients with parasitaemia was lower in both treatment groups without statistically significant difference (RR 0.69, 95% CI 0.47 to 1.01; participants = 2978; studies = 6; I² = 21, Additional file 6: S6) and (RR 1.46, 95% CI 0.40 to 5.36; participants = 2978; studies = 6; I² = 0%, Additional file 6: S6).

---

**Fig. 4** Forest plot of comparison: Dihydroartemisinin piperaquine versus artemether–lumefantrine, outcome: PCR-adjusted treatment failures at day 28

**Fig. 5** Forest plot of comparison: Dihydroartemisinin–piperaquine versus artemether–lumefantrine, outcome: 1.3 PCR-unadjusted treatment failures at day 42

**Fig. 6** Forest plot of comparison: Dihydroartemisinin piperaquine versus artemether–lumefantrine, outcome: PCR-adjusted treatment failures at day 42
Gametocytes

Gametocyte carriage at baseline

There was no significant difference in the appearance of gametocytes at baseline between two treatment groups (RR 0.71, 95% CI 0.46 to 1.10; participants = 2083; studies = 5; I² = 61%, Additional file 7: S7).

Gametocyte carriage  The overall gametocyte appearance at day 1–14 and 29–42 was significantly lower in patients treated with AL than DHA–PQ (RR 3.82, 95% CI 1.27 to 11.47; participants = 1484; studies = 4; I² = 0%, Fig. 7) and (RR 0.26, 95% CI 0.12 to 0.56; participants = 623; studies = 2; I² = 0%, Fig. 7). However, at day 15–28, the appearance of gametocyte carriage was lower in both treatment groups and there was no significant difference in the appearance of gametocyte in both groups (RR 0.25, 95% CI 0.04 to 1.69; participants = 1474; studies = 4; I² = 36%, Fig. 7) and (RR 0.43, 95% CI 0.11 to 1.65; participants = 599; studies = 1; I² = 0%, Fig. 7).

Anaemia

Mean haemoglobin (g/dL) at baseline

No significant difference was found in the mean haemoglobin (g/dL) at baseline in both treatment groups (MD 0.06, 95% CI 0.07 to 0.18; participants = 2982; studies = 6; I² = 0%, Additional file 8: S8).

Mean haemoglobin (g/dL) at Day 28 and 42

All five studies reported some measure of haematological recovery from baseline to day 28 in both treatment groups and no significant difference was found between...
the two groups in haematological recovery (Day 28, MD 0.04, 95% CI −0.19 to 0.27; participants = 778; studies = 2; I² = 0%, Additional file 8: S8). However, there was significant haematological recovery found among patients treated with DHA–PQ than AL at (Day 42, MD 0.35, 95% CI 0.12 to 0.59; participants = 1434; studies = 3; I² = 35%, Additional file 8: S8).

Adverse event

Gastrointestinal

Studies reported vomiting, anorexia, and abdominal pain as an adverse event. However, no significant difference was found between the two intervention groups (RR 0.94, 95% CI 0.78 to 1.12; participants = 2575; studies = 6; I² = 0%, Fig. 8), (RR 0.96, 95% CI 0.83 to 1.12; participants = 2575; studies = 6; I² = 0%, Fig. 8), and (RR 0.91, 95% CI 0.64 to 1.31; participants = 574; studies = 4; I² = 42%, Fig. 8).

Diarrhoea

Six studies reported diarrhoea as an adverse event. Diarrhoea was slightly more frequent in patients treated with DHA–PQ, but it was not statistically significant. Hence, there was no significant difference on the risk of diarrhoea in both treatment groups (RR 1.14, 95% CI 0.88 to 1.47; participants = 2575; studies = 6; I² = 57%, high quality of evidence, Fig. 9).

In one study [42], considering 63 days of follow-up among all 837 treatments with study drugs; 415 adverse events due to cough (373 mild and 42 moderate severity), 179 adverse events due to diarrhea (168 mild, 10 moderate, and one severe), and 56 adverse events due
to vomiting (all mild) were reported. Any adverse event due to cough, diarrhea, or vomiting occurred in 296 of 412 (72%) treatments with AL and 313 of 425 (74%) treatments with DHA–PQ. There were no statistically significant differences in the risks of these adverse events between the treatment arms for any time interval.

**Neuropsychiatric**

Studies reported headache and weakness or malaise as an adverse event and there was no significant difference between the two treatment groups (RR 0.80, 95% CI 0.46 to 1.39; participants = 237; studies = 1, Fig. 9) and (RR 0.91, 95% CI 0.76 to 1.09; participants = 2575; studies = 6; I² = 0%, Fig. 10).

**Cardiorespiratory**

Six studies reported cough as an adverse event. However, compared to AL, DHA–PQ was associated with a slightly higher frequency of cough (RR 1.07, 95% CI 1.01 to 1.13; participants = 2575; studies = 6; I² = 0%, Fig. 11). In the other hand, studies reported that coryza and pallor were also slightly more frequent in patients treated with DHA–PQ than AL, but no significant difference have found between the two treatment group (RR...
### Fig. 11: Forest plot of comparison: Dihydroartemisinin–piperaquine versus artemether–lumefantrine, outcome: other adverse events: Cardio-respiratory

| Study or Subgroup | DHA-PQ | AL | Risk Ratio M-H, Random, 95% CI |
|-------------------|--------|----|--------------------------------|
|                   | Events | Total | Events | Total | Weight |
| 1.17.1 Cough      |        |       |        |       |        |
| Karnya 2007       | 136    | 211   | 133    | 210   | 16.0%  |
| Yeka 2008         | 164    | 213   | 150    | 198   | 28.5%  |
| Atinsa 2009       | 177    | 351   | 153    | 320   | 13.9%  |
| Yeka 2013         | 47     | 72    | 20     | 35    | 3.0%   |
| Kakaru A 2014     | 64     | 165   | 74     | 201   | 4.8%   |
| Yeka 2019         | 233    | 299   | 203    | 300   | 33.9%  |
| Subtotal (95% CI) | 1311   | 1264  | 100.0% |
| Total events      | 821    | 733   |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 3.67, df = 5 (P = 0.60); I^2 = 0% |
| Test for overall effect: Z = 2.36 (P = 0.02) |

### Fig. 12: Forest plot of comparison: Dihydroartemisinin–piperaquine versus artemether–lumefantrine, outcome: other adverse events: Musculoskeletal/dermatological

| Study or Subgroup | DHA-PQ | AL | Risk Ratio M-H, Random, 95% CI |
|-------------------|--------|----|--------------------------------|
|                   | Events | Total | Events | Total | Weight |
| 1.18.1 Skin rash  |        |       |        |       |        |
| Yeka 2019         | 56     | 299   | 42     | 300   | 100.0% |
| Subtotal (95% CI) | 299    | 300   | 100.0% |
| Total events      | 56     | 42    |
| Heterogeneity: Not applicable |
| Test for overall effect: Z = 1.56 (P = 0.12) |

| Study or Subgroup | DHA-PQ | AL | Risk Ratio M-H, Random, 95% CI |
|-------------------|--------|----|--------------------------------|
|                   | Events | Total | Events | Total | Weight |
| 1.18.2 Pruritus   |        |       |        |       |        |
| Karnya 2007       | 14     | 211   | 22     | 210   | 39.3%  |
| Yeka 2008         | 8      | 213   | 3      | 198   | 20.4%  |
| Yeka 2019         | 24     | 299   | 16     | 300   | 40.4%  |
| Subtotal (95% CI) | 723    | 708   | 100.0% |
| Total events      | 46     | 41    |
| Heterogeneity: Tau^2 = 0.26; Chi^2 = 5.32, df = 2 (P = 0.07); I^2 = 62% |
| Test for overall effect: Z = 0.45 (P = 0.65) |
Musculoskeletal/dermatological
Studies reported skin rash and pruritus as an adverse event and no significant difference was found between the two treatment groups (RR 1.34, 95% CI 0.93 to 1.93; participants = 599; studies = 1; I² = 0%, Fig. 12) and (RR 1.19, 95% CI 0.56 to 2.50; participants = 1431; studies = 3; I² = 62%, Fig. 12).

Serious adverse event
Four studies reported 18 serious adverse events in DHA–PQ and 11 in the AL treatment group. However, the distributions of serious adverse events were not significantly different in the two treatment groups (RR 1.55, 95% CI 0.72 to 3.33; participants = 2105; studies = 4; I² = 0%, Fig. 13). All serious adverse events were judged to be unrelated to study medications. No death has occurred in all studies. However, in one study [42] there were only five serious adverse events (two in the AL group and three in the DP group) and all were due to the development of severe anemia, which was likely a consequence of malaria and not the study drugs.

Quality of the evidence
The quality of the evidence in this review was assessed using the GRADE approach and presented the evidence in six summary of findings tables for efficacy and safety (Summary of findings for the main comparison; Additional file 9: Additional Tables).

The evidence that DHA–PQ is more effective than AL at day 28, 42, and 63 unadjusted by genotyping was of low, moderate, and very low quality of evidence. There was considerable heterogeneity between studies at day 28 and 63. In addition, DHA–PQ consistently superiority over AL at day 42 adjusted by genotyping was of high quality of evidence and both DHA–PQ and AL performed better than the WHO standard of 5% PCR-adjusted treatment failure at day 28 in all trials (moderate quality of evidence). The quality of evidence was assessed on comparative adverse effects; cough slightly more frequent in DHA–PQ arm was of high quality of evidence. Generally, the quality of evidence of safety of the two treatments ranges from low to high quality.

Discussion
Summary of findings
This systematic review and meta-analysis focused on the safety and efficacy of DHA–PQ and AL for the treatment of uncomplicated falciparum malaria in children. The main finding of this meta-analysis is that the PCR unadjusted risk of recurrent falciparum parasitaemia at day 28 and 42 was significantly lower for participants treated with DHA–PQ than those treated with AL (low and moderate quality of evidence).

Early treatment failure was observed in three patients from the DHA–PQ group and 16 from the AL group had an early treatment failure in the three trials. At day 28, the PCR adjusted treatment failure was below 5% in both treatment arms without significant difference between the two treatment groups were observed (moderate quality of evidence). The PCR adjusted treatment failure day 42 was significantly lower for participants treated with DHA–PQ than those treated with AL (high quality of evidence). Nevertheless, at day 63 the PCR adjusted treatment failure in participants treated with AL was significantly lower than those who are treated with DHA–PQ (moderate quality of evidence).
The appearance of gametocyte at day 29–42 was significantly lower in patients treated with DHA–PQ than AL (moderate quality of evidence). In addition, in this review, most of the adverse events were mild or moderate severity and consistent with symptoms due to malaria. However, some adverse events like cough, anorexia, diarrhoea, and vomiting were the most common adverse events. In most studies, no significant difference was found in the proportion of study participants who experienced an adverse event of moderate and great severity between the DHA–PQ and AL treatment groups. But, cough was significantly more frequent in patients treated with DHA–PQ than AL (high quality of evidence).

**Public health implications**
The observed high efficacy of DHA–PQ was similar to that of other studies conducted in Africa [43, 44] and a high transmission setting in Indonesia [45]. However, in a study done in Somalia, the recurrence of parasitaemia was lower in DHA–PQ as compared to AL arm [46] and after day 3, in both treatment groups none of the participants were parasitaemic. However, PfK13 non-synonymous mutations (R622I) with unknown impact on the parasite resistance phenotype have been seen at a very low rate.

Recent studies conducted in Mali, Somalia, Angola, and Papua New Guinea also reported that both DHA–PQ and AL were highly effective in the treatment of uncomplicated falciparum malaria [8, 47–49]. Similarly, a former review also reported that in Asia and Oceania, PCR-adjusted treatment failure rate at day 28 was similar between treatments [23]. However, one study conducted in Cambodia–Thailand border reported high recrudescent on DHA–PQ treatment group [50] and this might be related to artemisinin resistance in the sub-region [51, 52]. The reason for the rapid occurrence of DHA–PQ resistance in this sub-region unknown; however, pre-existing circulation of parasites resistant to artemisinin or PQ in this area was probably a major mediator for their evolution to multidrug resistance. Furthermore, two studies conducted in Angola in 2013 and 2015 reported PCR adjusted cure rate of 88% in AL at one site [53, 54]. This result is lower compared to other previous studies conducted in different sub-Saharan African countries [46, 55, 56]. Despite this, those patients who were enrolled in both Angolan studies took the evening doses of AL at home without any supervision, and the higher treatment failure rate might be explained by this.

Similarly, a recent study in Rwanda reported that 42 day PCR corrected efficacy was significantly better in patients with falciparum malaria treated with DHA–PQ [57]. Hence, Studies conducted in western Kenya and Mali reported that the risk of treatment failure in both group was below 5% at day 42 [44]. For interventions such as mass drug administrations or seasonal malaria prevention [58], an ACT which protects against subsequent infections, such as DHA–PQ [59], could play a crucial role.

In this review several studies using microscopic detection of gametocytes have shown no difference [17, 56, 60–62] and an increased risk of gametocyte detection after treatment with DHA–PQ [36, 43, 63]. Consequently, membrane-feeding experiments have confirmed that both microscopic and sub-patent gametocytaemia result in infectivity to mosquitoes, with a positive association between gametocyte density and mosquito infection rates [64]. Increasing age and recurrent parasitaemia were associated with an increased risk of first detection of gametocytes after therapy [65], but the estimated mean duration of gametocytaemia for children below 5, children from 5 to 9 and children 10 years and above was 9.4, 7.8, and 4.1 days, respectively [66]. Furthermore, one previous study have reported that prolonged gametocytaemia after treatment could be an early sign of the occurrence of drug resistance, which is also the case in the emergence of recrudescence infections [67].

In this systematic review, significant haematological recovery from the baseline has been observed among patients treated with AL than DHA–PQ at day 42. Recent studies in Africa have reported that there was significant haematological recovery from the baseline in both treatment groups [44, 56]. One study in Tanzania reported a significant increase in serum haemoglobin level in AL treatment arm at day 28 than DHA–PQ [55]. However, patients enrolled in one site had relatively high haemoglobin at baseline and maintained throughout the follow-up period. This might be related to the difference in nutritional status and other health conditions associated with anaemia, such as helminthic infections and concurrent infections [68–70]. Age difference could also be the reason for this [55]. Studies done elsewhere in Africa [55, 71, 72] reported that improvements in haemoglobin during follow-up could suggest that malaria might be a major causing factor to anaemia and the low haemoglobin levels at recruitment.

A recent study in Papua New Guinea reported a high frequency of cough without significant difference between the two treatment groups [47]. A former study conducted in Zambia reported a high frequency of cough in DHA–PQ group than AL [18]. A study on AL and DHA–PQ safety and tolerability reported cough, diarrhoea, vomiting, and anaemia as the most commonly reported adverse events [42]. In a review done in Asia, gastrointestinal complaints were the most common adverse events associated with DHA–PQ, with no evidence of severe drug toxicity [73] and recent study in Africa also reported vomiting as a common adverse event.
in patients treated with DHA–PQ [74]. In breastfeeding infants DHA–PQ has previously been linked to an increased risk of vomiting [75]. The mechanism accountable for the increased risk of early vomiting among breastfeeding participants treated with DHA–PQ is not known. However, the temporal relationship suggests that the susceptibility of gastric mucosa of breastfed infants could be related to the pro-emetic effect of piperaquine than that in weaned infants [75]. To determine whether the co-administered milk may also affect this interaction further assessment might be needed. However, the absence of effect with AL implies that the mechanism is given to DHA–PQ, most likely piperaquine.

In this systematic review, four studies reported 21 serious adverse events in DHA–PQ and 13 in the AL treatment group. However, the distributions of serious adverse events were not significantly different in the two treatment groups. All serious adverse events were not related to study medications. No death has occurred in any of the studies. This might be justified by the fact that these studies were conducted among participants with uncomplicated malaria rather than the severe form which can lead to death.

Treatment failure could be occurred due to the drug’s ineffectiveness or development of resistance, as it may be due to insufficient drug levels [65]. Furthermore, treatment failure may occur due to resistance, sub-therapeutic levels that may occur due to non-adherence, or inadequate absorption. To identify risk factors for treatment failure further studies should be conducted. Also, further trials with detailed descriptions of patients’ characteristics with recrudescence are also very important. Besides, to investigate the association of AL and DHA–PQ resistance in the places where *Plasmodium falciparum* is endemic molecular surveillance may also play an important role in detecting genetic markers.

**Study limitations**

The study has some limitations. A majority of included studies were conducted in Tororo District Eastern region Uganda where malaria transmission intensity is high. The result of this study might not be representative of other regions in Uganda where malaria transmission intensity is low and moderate. Most studies reported treatment failure at 28 and 42 days, this review might not provide strong evidence about the long-term post-treatment prophylactic effect of the two drugs.

**Conclusion**

This systematic review provides comprehensive evidence about the treatment efficacy and safety of ACT in children in an area of malaria-endemic areas in Uganda. The overall parasite clearance, drug efficacy, and safety were good enough. Compared to AL, DHA–PQ appeared to reduce treatment failure and gametocyte carriage in Ugandan children. This may trigger DHA–PQ to become the first-line treatment option. Both treatments were safe and tolerable. As ACT resistance is emerging in different parts of the world, continuous studies that measure the efficacy of DHA–PQ and AL with 42 and 63 days follow-up are needed.
using the GRADE approach. DB, EDZ, HAT, EG, MJ (second authors), and TM were responsible for the quality assessment and reviewing the manuscript. All authors read and approved the final manuscript.

Funding
This review did not receive any specific grant.

Availability of data and materials
All relevant data are within the manuscript and its additional information files.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
We declare that they have no competing interests.

Author details
1 College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, PO. Box 9086, Addis Ababa, Ethiopia. 2 Department of Nursing, College of Health Science and Medicine, Dilla University, Dilla, Ethiopia. 3 Department of Midwifery, College of Health Science, Bule-Hora University, Bule-Hora, Ethiopia. 4 Department of Obstetrics and Gynecology, Saint Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia. 5 Hager Biomedical Research Institute, Asmara, Eritrea. 6 Arsi University, Asella, Ethiopia.

Received: 25 November 2020 Accepted: 24 March 2021

Published online: 01 April 2021

References
1. WHO. World malaria report 2019. Geneva: World Health Organization, 2019. https://www.who.int/malaria/publications/world-malaria-report-2019/en/.
2. WHO. Guidelines for treatment of malaria. 3rd edn. Geneva: World Health Organization. 2015. https://www.who.int/malaria/publications/atoz/9789241549127/en/.
3. WHO. Malaria factsheets. Geneva: World Health Organization, 2020. https://www.who.int/news-room/fact-sheets/detail/malaria.
4. Ministry of Health Republic of Uganda. National Malaria Control Programme. https://www.health.go.ug/programs/national-malaria-control-program/.
5. President’s malaria initiative. Uganda, Malaria Operational Plan FY 2018. Kampala. 2018. https://www.pmi.org/place/where-we-work/uganda/.
6. WHO. World MALARIA Report 2014. Geneva: World Health Organization. 2014. https://www.who.int/malaria/publications/world_malaria_report_2014/en/.
7. WHO. Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2010. https://www.ncbi.nlm.nih.gov/books/NBK254223/pdf/Bookshelf_NBK254223.pdf.
8. Plucinski MM, Dimbu PR, Macaia AP, Ferreira CM, Samuelondo C, Quivinja J, et al. Efficacy of artesunate-lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015. Malar J. 2017;16:62.
9. Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, Félix J, et al. Efficacy and safety of artesunate–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the three provinces in Angola, 2017. Malar J. 2018;11:144.
10. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.
11. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.
12. Dogovski C, Xie SC, Burgio G, Bridgford J, Mok S, McCaw JM, et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol. 2015;13:e1002132.
13. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013;57:914–23.
14. WHO. Artemisinin and artemisinin-based combination therapy resistance. Status report. Geneva: World Health Organization, 2017. https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/.
15. Agarwal A, McMorrow M, Oranyo P, Otiemo K, Odero C, Williamson J, et al. A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperazine in the treatment of uncomplicated malaria among children in western Kenya. Malar J. 2013;12:254.
16. Ebenebe JC, Ndadom G, Ambe J, Wammanda R, Jiya N, Finomo F, et al. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children ten years following adoption as first-line antimalarials. Am J Trop Med Hyg. 2018;99:649–64.
17. Grandesso F, Guindo O, Woi Messe L, Makarimi R, Traore A, Dama S, et al. Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. Malar J. 2018;17:52.
18. Namboni M, Van Veertuenden JP, Hachiosu V, Chapolinda M, Mukwama-taba D, Mulenga M, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J. 2011;10:50.
19. European Medicines Agency. Eurartesim (dihydroartemisinin-piperaquine) 20 mg/160 mg and 40 mg/320 mg film-coated tablets: EU summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/eurartesim-epar-product-information_en.pdf.
20. Amaratunga C, Lim P, Suon S, Steng S, Mao S, Soph C, et al. Dihydroartemisinin-piperazine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357–65.
21. Kwenti TE. Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies. Res Rep Trop Med. 2018;9:123–36.
22. Katrak S, Day N, Ssemomondo E, Kwarisima D, Midekisa A, Greenhouse B, et al. Community-wide prevalence of malaria parasitemia in HIV-infected and uninfected populations in a high-transmission setting in Uganda. J Infect Dis. 2016;213:1971–8.
23. Zani B, Gathu M, Donegan S, Ollario PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014,2014:CD010927.
24. Assefa D, Zeleke ED. Systematic review and meta-analysis of the efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in infants and children in Uganda, 2020. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD4201823354.
25. Shamseer L, Moher D, Clarke M, Gherisi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
26. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, 2011. www.cochrane-handbook.org.
27. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization, 2009. https://www.who.int/malaria/publications/atoz/9789241597531/en/.
28. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, et al. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane. 2021. www.training.cochrane.org/handbook.
29. Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane. 2021. www.training.cochrane.org/handbook.
30. Muhindo MK, Kakuru A, Jagganathan P, Talsuna A, Osilo E, Orukan F, et al. Early parasite clearance following artemisinin-based combination

Page 23 of 25

Assefa et al. Malar J (2021) 20:174
therapy among Ugandan children with uncomplicated *Plasmodium falciparum* malaria. Malar J 2014;13:32.
31. Cochrane Community. GRADEproGDT. McMasterUniversity (developed by Evidence Prime). 2020. https://gradeopro.org/
32. Schünemann H, Brozek J, Guyatt G, Oxman A. Introduction to GRADE handbook (Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach). 2013. https://gradeopro.org/
33. Higgins JPT, Savovic J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. Cochrane handbook for systematic reviews of interventions, version 5.0 (updated July 2019). Cochrane. 2019. www.tutoring.cochrane.org/handbook
34. Guyatt GH, Oxman AD, Kunz R,ücker C, Vist GE, GRADE Working Group. GRADE Handbook (Handbook for grading the quality of evidence and the strength of recommendations). 2018. wwwGRADE.ORG.
35. Guyatt GH, Oxman AD, Kunz R,ücker C, Vist GE, GRADE Working Group. GRADE Handbook (Handbook for grading the quality of evidence and the strength of recommendations). 2018. wwwGRADE.ORG.
36. Four Artemisinin-Based Combinations Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated *Plasmodium falciparum* malaria in African children: a randomized trial. PLoS Med. 2011;8:e1001119.
37. Yeka A, Tibenderana J, Acham J, D’Alejandro U, Talisuna AC. Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children. PLoS ONE. 2013;8:e53772.
38. Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis. 2014;59:509–16.
39. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakijabiri J, Staedke SG, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;2:e20.
40. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakijabiri J, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE. 2008;3:e2390.
41. Yeka A, Wallender E, Mulebeke R, Kibuuka A, Kigozi R, Bosco A, et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children. J Infect Dis. 2019;219:1112–20.
42. Katrook S, Gasirwira A, Arinaitwe E, Kakuru A, Wanzira H, Bigira V, et al. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J 2009;8:272.
43. Onyamboko MA, Fanello CI, Wongsaen K, Tarning J, Cheah PY, Tshefu A, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria in the Democratic Republic of the Congo. Antimicrob Agents Chemother. 2014;58:5528–36.
44. Ratcliffe A, Siwandho T, Kenangale E, Mariesta R, Wuwung RM, Laihad RR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Malawi. Malar J 2018;17:347.
45. Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in children in Zaire and Uige Provinces, angola. Antimicrob Agents Chemother. 2015;59:437–43.
46. Mandara CI, Kavishe RA, Gesase S, Mghamba J, Ngadya E, Mmbuji P, et al. High efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Muheza and Kigoma Districts, Tanzania. Malar J 2018;17:261.
47. Uwimana A, Penkunas MJ, Nisingizwe MP, Warsame M, Umulisa N, Uyyizey D, et al. Efficacy of artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial. Trans R Soc Trop Med Hyg. 2019;113:312–9.
48. WHO. Policy recommendation: seasonal malaria chemoprevention (SMC) for *Plasmodium falciparum* malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Geneva: World Health Organization. 2012. https://www.who.int/malaria/publications/atoz/who_smc_policy_recommendation/en/.
49. Bretsher MT, Griffin JT, Hugo P, Baker M, Ghan N, Okell L. A comparison of the duration of post-treatment protection of artemether-lumefantrine, dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated malaria. Malar J 2014;13:919.
50. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Burkina Faso. Clin Infect Dis. 2007;45:1453–61.
51. Yavo W, Faye B, Kuate T, Djohan V, Oga SA, Kassi RR, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated *Plasmodium falciparum* malaria in sub-Saharan Africa. Malar J 2011;10:198.
52. Omoni B, Burugu M, Matoke-Muhia D, Too E, Nambiati EA, Chege W, et al. Gametocytoreduction in children, from western Kenya, with uncomplicated *Plasmodium falciparum* malaria after artemether-lumefantrine or dihydroartemisinin-piperaquine treatment. Malar J 2019;18:398.
53. WWARN Gametocyte Study Group. Gametocyte carriage in uncomplicated *Plasmodium falciparum* malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Med. 2016;14:79.
54. Ouedraogo AL, Bousema T, Schneider P, de Vlas SJ, Ilboudo-Sanogo E, Robert NG, et al. Treatment failure of dihydroartemisinin-piperaquine for *Plasmodium falciparum* malaria, Vietnam. Emerg Infect Dis. 2017;23:715–7.
55. Plucinski MM, Dimbri PR, Macaia AP, Ferreira CM, Samutondo C, Quvinja J, et al. Efficacy of artesunate-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated *Plasmodium falciparum* malaria in Angola, 2015. Malar J 2017;16:62.
56. Plucinski MM, Talundzic E, Morton L, Dimbri PR, Macaia AP, Fortes F, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uige Provinces, angola. Antimicrob Agents Chemother. 2015;59:437–43.
57. Uwimana A, Penkunas MJ, Nisingizwe MP, Warsame M, Umulisa N, Uyyizey D, et al. Efficacy of artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial. Trans R Soc Trop Med Hyg. 2019;113:312–9.
58. WHO. Policy recommendation: seasonal malaria chemoprevention (SMC) for *Plasmodium falciparum* malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Geneva: World Health Organization. 2012. https://www.who.int/malaria/publications/atoz/who_smc_policy_recommendation/en/.
66. Bousema JT, Gouagna LC, Drakeley CJ, Meustege AM, Okech BA, Akim IN, et al. *Plasmodium falciparum* gametocyte carriage in asymptomatic children in western Kenya. *Malar J.* 2004;3:18.

67. Delves MJ, Ruecker A, Strachil U, Leelievre J, Marques S, Lopez-Barragan MJ, et al. Male and female *Plasmodium falciparum* mature gametocytes show different responses to antimalarial drugs. *Antimicrob Agents Chemother.* 2013;57:3268–74.

68. Ngui R, Lim YA, Chong Kin L, Sek Chuen C, Jaffar S. Association between anaemia, iron deficiency anaemia, neglected parasitic infections and socioeconomic factors in rural children of West Malaysia. *PLoS Negl Trop Dis.* 2012;6:e1550.

69. Magalhaes RJ, Clements AC. Mapping the risk of anaemia in preschool-age children: the contribution of malnutrition, malaria, and helminth infections in West Africa. *PLoS Med.* 2011;8:e1000438.

70. Sousa-Figueiredo JC, Gamboa D, Pedro JM, Fancony C, Langa AJ, Magalhaes RJ, et al. Epidemiology of malaria, schistosomiasis, geohelminths, anemia and malnutrition in the context of a demographic surveillance system in northern Angola. *PLoS ONE.* 2012;7:e33189.

71. Shayo A, Buza J, Ishengoma DS. Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. *Malar J.* 2015;14:135.

72. Ndiaye JL, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, et al. Repeated treatment of recurrent uncomplicated *Plasmodium falciparum* malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. *Malar J.* 2011;10:237.

73. Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. *Trans R Soc Trop Med Hyg.* 2007;101:858–66.

74. Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, Felix J, et al. Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria in three provinces in Angola. *Malar J.* 2018;17:144.

75. Creek D, Bigira V, Arinaitwe E, Wanzira H, Kakuru A, Tapper J, et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. *Am J Trop Med Hyg.* 2010;83:873–5.

76. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. *PLoS ONE.* 2009;4:e7871.

77. Kakuru A, Achan J, Muhindo MK, Ikilezi G, Arinaitwe E, Mwangwa F, et al. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. *Clin Infect Dis.* 2014;59:446–53.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.